Few Sector Leaders are in buy range, with most overextended or still in the midst of bases. But Alexion Pharmaceuticals (ALXN) has recovered to just below a failed breakout entry. The stock emerged past a 172.60 cup-with-handle buy point on July 23, ahead of its Q2 earnings report. Early July 24, the biotech reported results that topped views and raised its earnings and sales forecasts for the full year.